HomeCompareSGCSF vs PFE

SGCSF vs PFE: Dividend Comparison 2026

SGCSF yields 100000.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGCSF wins by $4.832206901976048e+26M in total portfolio value
10 years
SGCSF
SGCSF
● Live price
100000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.832206901976048e+26M
Annual income
$482,271,988,201,431,700,000,000,000,000,000.00
Full SGCSF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — SGCSF vs PFE

📍 SGCSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGCSFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGCSF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGCSF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGCSF
Annual income on $10K today (after 15% tax)
$8,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$409,931,189,971,216,900,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, SGCSF beats the other by $409,931,189,971,216,900,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGCSF + PFE for your $10,000?

SGCSF: 50%PFE: 50%
100% PFE50/50100% SGCSF
Portfolio after 10yr
$2.416103450988024e+26M
Annual income
$241,135,994,100,715,840,000,000,000,000,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SGCSF
No analyst data
Altman Z
-33.5
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGCSF buys
0
PFE buys
0
No recent congressional trades found for SGCSF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGCSFPFE
Forward yield100000.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.832206901976048e+26M$51.1K
Annual income after 10y$482,271,988,201,431,700,000,000,000,000,000.00$27,210.54
Total dividends collected$4.8315851896727036e+26M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGCSF vs PFE ($10,000, DRIP)

YearSGCSF PortfolioSGCSF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,010,700$10,000,000.00$9,161$701.38+$10.00MSGCSF
2$9,366,505,842$9,355,794,392.52$8,610$859.79+$9366.50MSGCSF
3$8,191,091,111,834$8,181,068,950,583.78$8,366$1,081.25+$8191091.10MSGCSF
4$6,695,134,751,499,451$6,686,370,284,009,789.00$8,483$1,405.66+$6695134751.49MSGCSF
5$5,114,850,040,116,031,000$5,107,686,245,931,928,000.00$9,084$1,907.24+$5114850040116.02MSGCSF
6$3,652,290,278,277,141,000,000$3,646,817,388,734,216,400,000.00$10,418$2,732.78+$3652290278277141.00MSGCSF
7$2,437,583,176,648,375,000,000,000$2,433,675,226,050,619,000,000,000.00$13,007$4,193.56+$2437583176648375296.00MSGCSF
8$1,520,612,508,079,010,700,000,000,000$1,518,004,294,079,997,000,000,000,000.00$18,010$7,005.87+$1.5206125080790106e+21MSGCSF
9$886,637,379,601,106,600,000,000,000,000$885,010,324,217,461,900,000,000,000,000.00$28,216$12,979.89+$8.866373796011065e+23MSGCSF
10$483,220,690,197,604,800,000,000,000,000,000$482,271,988,201,431,700,000,000,000,000,000.00$51,081$27,210.54+$4.832206901976048e+26MSGCSF

SGCSF vs PFE: Complete Analysis 2026

SGCSFStock

Australian Oil is an Australian-based energy company focused on under-explored, recently over-looked, world class oil and gas opportunities near under-supplied markets. The Company is currently focused on conventional oil and gas exploration and production in the Sacramento Basin in California. Australian Oil has a portfolio of natural gas and oil producing wells in addition to prospects and discoveries at various exploration and appraisal stages. AOK is in the process of evaluating the acquisition of oil and gas producing and exploration assets to enhance the Company's strategic needs and deliver shareholder value.

Full SGCSF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SGCSF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGCSF vs SCHDSGCSF vs JEPISGCSF vs OSGCSF vs KOSGCSF vs MAINSGCSF vs JNJSGCSF vs MRKSGCSF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.